Sarvan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sarvan

Quick Facts

Property Description
Active ingredient Valsartan
Form Film-coated tablets
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Management of high blood pressure
Origin Synthetic non-peptide compound

What is Sarvan: Definition and Pharmacological Classification

Sarvan is a prescription-only cardiovascular medicine containing the active ingredient Valsartan that supports heart function and manages high blood pressure. It is an Angiotensin II Receptor Blocker (ARB), placing it within the sartan class of antihypertensive agents.

Composition, Origin, and Pharmaceutical Form

The core component, Valsartan, is a synthetic non-peptide compound derived structurally from the amino acid L-Valine. Sarvan is supplied as film-coated tablets for oral administration, which is the conventional and stable pharmaceutical preparation for long-term systemic antihypertensive therapy. This formulation generally contains Valsartan as the sole active ingredient (monotherapy), providing a basis for daily dosing and effect.

General Purpose and High-Level Action

The primary purpose of Sarvan is to facilitate better cardiovascular health by achieving a sustained lowering of blood pressure. This benefit results directly from its physiological action: the drug works by selective and specific inhibition, preventing the vasoconstrictive hormone Angiotensin II from binding to the AT1 receptors found in blood vessels. This effect leads to a reduction in vascular resistance, thereby decreasing the overall force and workload placed on the heart and circulatory system.

Regulatory References

  1. Valsartan FDA Label

What side effects are possible with Sarvan?

Possible Side Effects and Safety Information

The safety profile of Sarvan (Valsartan) is formally documented by government regulatory bodies, classifying adverse reactions by frequency and the body system affected. This regulatory framework defines the established risks and essential safety constraints associated with the medicine.


Adverse Reaction Scope and Classification

Adverse reactions are organized into System-Organ Classes (SOCs) and categorized by their incidence:

Feature Regulatory Documentation Summary
Common Side Effects Dizziness, hypotension (low blood pressure), fatigue, viral infection, diarrhea, and upper respiratory tract infection.
Uncommon Side Effects Syncope (fainting), vertigo, cough, renal impairment, and hyperkalemia (high potassium levels).
Involved System-Organ Classes Effects documented across Nervous System (dizziness, vertigo), Vascular Disorders (hypotension), Renal/Urinary Disorders (renal impairment), and Metabolism/Nutrition Disorders (hyperkalemia).

Serious Adverse Reactions and Safety Constraints

Regulatory documents explicitly identify specific safety considerations and rare but clinically significant adverse reactions:

Feature Official Safety Statement Summary
Serious Reactions Angioedema (swelling beneath the skin), Acute Renal Failure, Severe Hypotension, and Neutropenia (a hematological effect) are noted as serious adverse events.
Population Constraints The medicine is contraindicated during the second and third trimesters of pregnancy due to risk of fetal injury. Use is not recommended in individuals with severe hepatic impairment.
Exposure Patterns Orthostatic effects and dizziness are noted as potentially more common at the initiation of treatment or during dose adjustments.
Co-administration Limitations Use is not recommended in combination with aliskiren in patients with Type 2 diabetes due to safety concerns.

This structure ensures a neutral, evidence-based description of the medicine's safety characteristics, outlining both the more frequent effects and the specific, mandatory limitations on its use.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations and required emergency actions for Sarvan (Valsartan) overdosage, as stated in regulatory prescribing information.


Documented Manifestations and Outcomes

The most likely clinical presentation of Sarvan overdosage is severe hypotension (low blood pressure), which is often accompanied by changes in heart rhythm. Officially documented cardiac effects include both tachycardia (fast heart rate) and bradycardia (slow heart rate). Reported severe consequences include depressed level of consciousness, circulatory collapse, and shock.


Required Emergency Actions

Immediate medical help or contact with a Poison Control Center is required for suspected overdosage. Urgent medical attention must be sought immediately if severe manifestations are observed, such as collapse, trouble breathing, or inability to be awakened. If symptomatic hypotension occurs, supportive treatment must be instituted by medical professionals.

Procedural Note Regulatory Statement
Antidote Availability No specific antidote is known.
Dialysis Efficacy Valsartan is not removed from the plasma by dialysis.

Available regulatory data related to overdosage in humans is noted as limited. Treatment for severe outcomes necessitates continuous medical monitoring in a hospital setting.

Therapeutic Uses of Sarvan

Sarvan is a medication considered relevant for the long-term management of cardiovascular conditions. This therapy is commonly used to help with conditions involving symptoms related to systemic imbalance, such as high blood pressure and symptomatic heart failure, and supports the long-term risk management following a myocardial infarction.

The medication is applied in addressing symptom clusters related to systemic imbalance and noticeable physiological strain. Sarvan is applied across domains where additional symptomatic support is needed to maintain functional stability. It assists in easing the overall symptom load and helps patients cope more steadily with chronic fluctuations. It is relevant in clinical settings marked by increased discomfort or tension, as treatment may assist with long-term stability.

Quick Fact: Relief for Vascular Strain

Therapeutic Area Primary Benefit
Hypertension Supports the management of blood pressure
Heart Failure Contributes to easing the risk of hospitalization
Post-MI Care Assists with maintaining functional stability

Sarvan is relevant for easing symptoms linked to organ-specific functional stress, particularly in high-risk patients with coexisting Type 2 diabetes and high blood pressure, where it supports the management of progressive kidney damage.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Sarvan (Based on RISVAN)

Official regulatory documents establish strict rules concerning who is eligible to use this medicine. These rules define populations that are absolutely excluded and those that require special medical consideration.

Absolute Exclusions

The medicine must not be used by the following groups, as they are formally contraindicated:

  • Patients with a known history of serious hypersensitivity reactions (e.g., anaphylaxis) to the active substance (risperidone) or any of the inactive ingredients.
  • Elderly patients with dementia-related psychosis. Use is not approved for this condition due to documented increased risks, including mortality.

Populations Requiring Restricted or Conditional Use

  • Pediatric Patients: Safety and effectiveness have not been established in children and adolescents under 18 years of age.
  • Organ Impairment: Patients with renal or hepatic impairment require prior dose titration with the oral form of the medication before beginning treatment.
  • Pregnancy and Lactation: Use during the third trimester of pregnancy carries a risk of extrapyramidal and/or withdrawal symptoms in the newborn. The active substance passes into breast milk, requiring a careful risk-benefit assessment by a healthcare provider.
  • Hematologic/Bleeding Risk: Patients with a history of low white blood cell count (WBC), leukopenia, or neutropenia require careful monitoring. Caution is also needed for individuals with significant bleeding disorders.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Sarvan (Valsartan) interactions are defined by regulatory authorities based on pharmacodynamic effects on fluid balance and renal function, as well as pharmacokinetic changes affecting drug exposure.

Contraindicated Combinations

Co-administration of Aliskiren is strictly prohibited in patients with Type 2 diabetes mellitus or those with moderate-to-severe renal impairment (GFR below 60 mL/min/1.73 m^2). This restriction addresses the severe risk associated with dual blockade of the Renin-Angiotensin System (RAS).

Documented Drug-Drug and Drug-Substance Interactions

Interacting Substance/Class Official Interaction Outcome (Regulatory Description)
Potassium-Sparing Diuretics, Supplements, and Salt Substitutes Co-administration may lead to increases in serum potassium (hyperkalemia), a documented pharmacodynamic effect.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May result in deterioration of renal function and attenuation of Sarvan's antihypertensive effect.
Lithium Reported to cause increases in serum lithium concentrations and subsequent toxicity.
Other RAS Blockers (e.g., ACE Inhibitors) Dual blockade is associated with increased risks of hypotension and hyperkalemia and is generally avoided.

Food Interaction and Exposure

Administration with food formally results in a substantial decrease in Valsartan exposure, reducing the Area Under the Curve (AUC) by 48% and the maximum concentration ( C max) by 59% compared to the fasted state. Valsartan is minimally metabolized, meaning clinically significant interactions via CYP450 enzyme inhibition are considered unlikely.

Mechanism of Action

How Sarvan Works

Sarvan exerts its effects by acting as a polypharmacological antagonist across several key receptor systems, leading to a cascade of changes that regulate central neuronal activity and peripheral vascular tone.


Blocking Serotonin 5- HT2A Receptors

This is Sarvan's primary mechanism, involving the antagonism of 5- HT2A receptors, mainly within the brain's cortex and limbic system. This action interrupts the excitatory signaling typically mediated by serotonin , which results in a reduction of overall excitatory signaling in central neuronal circuits. This mechanism's influence is linked to sleep architecture, specifically an increase in Slow-Wave Sleep (SWS).


Influencing Dopamine and Adrenergic Pathways

Sarvan also functions as an antagonist at dopamine D2 receptors and alpha-1 (alpha1) adrenergic receptors. The alpha1 antagonism in the peripheral vascular system causes blood vessel widening (vasodilation), which results in the physiological consequence of lowering blood pressure (hypotension). The alpha1 and D2 antagonism contributes to decreased arousal and reduced central nervous system excitability. This multi-target approach influences neurocognitive signaling and cardiovascular control simultaneously.

Dosage and Administration Information

Sarvan is an orally administered medication available as film-coated tablets in multiple strengths, ranging from 40 mg to 320 mg. The administration schedule is strictly defined by the clinical context.

For the long-term management of high blood pressure, the typical regimen is once daily, starting at 80 mg or 160 mg, and may be increased up to a maximum of 320 mg per day. In contrast, the protocol for symptomatic heart failure and post-myocardial infarction care requires the medicine to be taken twice daily, beginning with an initial dose of 20 mg or 40 mg twice daily. This initial dose is then progressively increased (titrated) as tolerated, with the maintenance target often set at 160 mg twice daily.

The medicine can be taken with or without food as the relationship to meals does not constrain administration timing. Dosage adjustments or restrictions are required for specific patient groups. For instance, the dose for patients with mild to moderate non-cholestatic hepatic impairment should not exceed 80 mg daily. Similarly, dosing for children aged 6 to 16 years with hypertension is weight-based. Full reduction in blood pressure is typically attained after four weeks of consistent therapy. If a dose is missed, patients should skip that dose if the next one is due soon and return to their regular schedule.

Recent Clinical Evidence

Evidence for use in Managing High Blood Pressure

Research examining Sarvan (valsartan) for High Blood Pressure (Hypertension) has primarily involved large-scale Randomized Controlled Trials (RCTs). These studies, lasting several years, were designed to evaluate the medicine against other treatments or control. Researchers monitored changes in systolic and diastolic blood pressure (BP) and definitive outcomes like the occurrence of stroke or myocardial infarction (heart attack), and cardiovascular mortality. Findings describe patterns observed where the medicine was evaluated for changes in blood pressure. Studies monitored these effects over several years, offering insight into how BP evolved in the observed populations. What remains uncertain is how non-BP-related outcomes compare precisely when different classes of blood pressure medications are used. The core evidence comes from comparisons, often in high-risk patients who had other conditions, such as Type 2 Diabetes.


Evidence for use in Symptomatic Heart Failure

For symptomatic heart failure, large, multinational Placebo-Controlled RCTs were conducted, primarily focusing on adults with reduced heart function (reduced ejection fraction). Researchers studied whether the medicine was associated with differences in all-cause mortality, cardiovascular mortality, and the frequency of hospitalizations for heart failure. Studies report how patient-reported outcomes describing perceived discomfort and functional status, measured using scales like the NYHA functional class, evolved in the observed populations. Evidence is more limited for patients with heart failure where the heart's pumping function is preserved (preserved ejection fraction). Furthermore, subgroup analysis noted that findings were mixed when the medicine was used in a specific three-drug combination.


Evidence for use Following a Myocardial Infarction

Research exploring use following a Myocardial Infarction (heart attack) focused on clinically stable adults who also showed signs of left ventricular dysfunction or failure. Large RCTs were conducted, sometimes comparing the medicine to other standard-of-care agents. Researchers monitored long-term rates of all-cause mortality, cardiovascular death, and the risk of recurrent heart attack or subsequent heart failure hospitalization. Studies observed and reported that the rates of cardiovascular events tracked were often similar to those observed for established active comparators.


Long-Term Studies and Follow-Up Duration

Evidence research explored regarding Sarvan and major cardiovascular events comes from studies that maintained long-term follow-up, often extending for three to five years. Studies focusing on initial BP control often had shorter follow-up durations, sometimes lasting only a few weeks. Evidence for long-term cardiovascular outcomes is primarily derived from the multi-year studies.


Evidence in Special Populations

Studies monitored outcomes in specific patient groups, such as adults with coexisting Type 2 Diabetes. For pediatric hypertension (children aged 6 to 16 years), studies focused on short-term changes in systolic and diastolic BP over approximately four weeks. Follow-up durations were limited in these studies, meaning there is limited information for long-term outcomes and the potential effects on growth and development are not fully established. Data for children under the age of 6 is insufficient.

Key Studies & References Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine

Frequently Asked Questions (FAQ)

Common questions about Sarvan (FAQ)


Q: What is the main condition Sarvan is officially approved to treat?

According to official product information, Sarvan (valsartan) is primarily indicated for lowering high blood pressure in adults and children over the age of six. It is also approved for treating symptomatic heart failure and for reducing the risk of cardiovascular death in patients who are clinically stable following a heart attack. This information is based on findings from regulatory studies.


Q: Is Sarvan in the same category as older medicines like ACE inhibitors?

Sarvan is classified as an Angiotensin II Receptor Blocker, or ARB. While ARBs and ACE inhibitors both target the body’s Renin-Angiotensin System (RAS) to regulate blood pressure, they work using different mechanisms. This distinction in action is noted in regulatory and authoritative drug safety documents.


Q: How long do the common side effects of Sarvan usually persist after starting treatment?

Official labeling for Sarvan indicates that side effects like dizziness or orthostatic effects (feeling lightheaded when standing up) may be more common when a patient first begins treatment. There is no specific duration quantified for how long all common side effects may persist, but these effects are typically tracked by the prescriber during the initial phases.


Q: What are the signs of a rare but serious side effect that require attention?

Regulatory documents identify angioedema (swelling beneath the skin) as a serious adverse reaction. Official warnings state that symptoms suggestive of angioedema, particularly of the face, tongue, or throat, or difficulty swallowing or breathing, should be reported to a healthcare professional without delay.


Q: Can I take Sarvan with vitamins or herbal supplements?

According to guidance from authoritative sources, there is often not enough specific safety information to confirm that all herbal remedies or supplements are safe when taken with prescription medication. It is important that a healthcare provider is informed of all non-prescription products, including supplements, that are being used.


Q: What are the main contraindications for Sarvan (who should absolutely not use it)?

Regulatory documents describe that Sarvan is not appropriate for use by individuals with a known serious allergy to the drug or its ingredients. It is also strictly contraindicated for patients with diabetes who are simultaneously taking the medicine Aliskiren. Furthermore, use during the second and third trimesters of pregnancy is strictly forbidden.


Q: What are the official warnings regarding Sarvan use during pregnancy or while breastfeeding?

Sarvan is strictly contraindicated during the second and third trimesters of pregnancy due to the risk of injury to the developing fetus, specifically affecting the lungs and kidneys. For breastfeeding, regulatory reviews indicate the active substance passes into breast milk, and the appropriateness of use is a matter for specific medical consultation.


Q: Does Sarvan cause a persistent cough, which is sometimes reported with similar medications?

Unlike some other blood pressure medicines, studies indicate the incidence of cough with Sarvan is low and comparable to that experienced with a placebo. The official mechanism of action for this type of medication is not associated with the buildup of substances that typically cause the persistent cough sometimes seen with older drug classes.


Q: Are there generic versions of Sarvan available, and how are they regulated?

The active ingredient in Sarvan, known as valsartan, is available in a generic form. Regulatory authorities, such as the FDA, confirm that generic versions contain the same active ingredient and meet requirements for safety, effectiveness, and quality as the brand-name product.


Q: What other health conditions are considered to be high-risk factors when starting Sarvan?

Official labeling highlights that special consideration is required for individuals with existing liver or kidney problems. Individuals who are volume- or salt-depleted (meaning they have low fluid or salt levels) are also noted to be at a higher risk of developing symptomatic low blood pressure when initiating treatment.


Q: Does Sarvan have any known effects on a person's weight (gain or loss)?

Postmarketing and clinical trial experiences for the active ingredient have noted both weight gain and weight loss as possible adverse effects. These reports often come from studies where Sarvan was used in combination with other medications.


Q: Will taking Sarvan impact my ability to drive or operate machinery?

Because Sarvan can potentially cause effects like dizziness or drowsiness, authoritative patient information suggests that activities requiring mental alertness, such as driving or operating heavy machinery, should be avoided until the medicine's effects are understood.


Q: Does Sarvan interact with alcohol, and what is the general guidance?

Alcohol can increase the blood pressure-lowering effect of Sarvan, which may elevate the risk of experiencing excessively low blood pressure, known as hypotension. Official drug warnings mention that alcohol can increase the risk of symptoms like dizziness or lightheadedness.


Q: Do I need to have regular blood tests or other monitoring while on Sarvan?

Regulatory documents state that monitoring of key indicators is necessary for patients susceptible to certain risks. This includes checks on kidney function and potassium levels.


Q: Is there a risk of withdrawal symptoms if Sarvan is stopped suddenly?

The official label does not specifically define a withdrawal syndrome for Sarvan. However, general pharmacological information indicates that abrupt cessation of any medicine used for high blood pressure may result in a return to pre-treatment high blood pressure levels.


Q: Can Sarvan tablets be safely split, crushed, or chewed for easier swallowing?

Official patient information states that the film-coated tablets are to be swallowed whole. Breaking, crushing, or chewing the tablet is described as inappropriate because it may alter how the medicine is absorbed by the body.


Q: Can taking Sarvan potentially affect blood sugar or cholesterol levels?

Official drug information mentions that high blood sugar (hyperglycemia) has been reported in postmarketing surveillance. Authoritative guidelines emphasize the importance of managing all cardiovascular risk factors, including blood sugar and cholesterol levels, as part of overall treatment.

How should Sarvan be stored and disposed of?

Sarvan (valsartan) tablets must be stored under specific environmental and physical conditions to maintain their stability and safety.

Storage Requirements

Detail Official Regulatory Requirement
Temperature Range Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Brief excursions are permitted between 15 C and 30 C (59 F and 86 F).
Environmental Protection Keep from freezing, and store away from excess heat, direct light, and excess moisture (such as in a bathroom).
Container Rule Must be kept in the original, tightly closed container.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Outdated or unneeded Sarvan must be properly discarded. Patients should ask a healthcare professional or pharmacist how to dispose of the medicine, following local guidelines and drug take-back programs. The medicine should not be flushed down a toilet or poured into a drain unless specifically instructed to do so by the manufacturer or a government authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sarvan found in:

A-Z Index: